

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application No. 10/526,697

Confirmation No. 9619

Applicant: Dudley et al.

Filed: May 5, 2005

TC/AU: 1644

Examiner: Michail A. Belyavskiy

Docket No.: 233876 (Client Reference No. E-275-2002/1-US-02)

Customer No.: 45733

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

DECLARATION UNDER 37 C.F.R. § 1.131 OF MARK E. DUDLEY


I, Mark E. Dudley, do hereby declare as follows:

1. I am a co-inventor of pending claims in the above-referenced patent application, along with Steven Rosenberg and John Wunderlich.
2. We conceived of and reduced to practice the claimed invention in the United States before July 2, 2001, as evidenced by the following:
 - a. attached to this Declaration is a true and accurate copy of a report prepared by myself. The report summarizes research performed involving the administration of ^{non-}myeloablative lymphodepleting chemotherapy followed by adoptive transfer of autologous T cells to melanoma patients.
3. The treatment dates of Patients A-F which have been deleted from the report are prior to July 2, 2001.
4. I hereby declare that all statements made herein of my own knowledge are true, that all statements made on information and belief are believed to be true,

In re Appln. of Dudley et al.
Application No. 10/526,697

that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: 11-14-2007


Mark E. Dudley, Ph.D.

Patient	ID Ref	Last	First	Treatment Characteristics			Current clinical		Patient Characteristics			Vax	AL	Other	DOD	prior xbl
				Date	Cells	AGE	PR (mo)	Neutro	Asp(Sm)	HLA	Sequences					
Patient A		A	Patient		33.0	A	PR (29)		180M	A02:A01	AX MT PV		2	IV		
Patient B		B	Patient		33.0	gA	PR (8)		10F	A01:A02	SK SU		2	IV	w/ clone	
Patient C		C	Patient		39.8	gA	NR		43F	A02:A01	SN SK SU		3	IV	w/ clones	
Patient D		D	Patient		34.0	gM	PR (2)		57F	A02:A29	SK		3	IV	w/ clone	
Patient E		E	Patient		30.0	gA	NR-M		150M	A02:A03	NR BN IL LU		2	IV	w/ clone	
Patient F		F	Patient		36.5	A	PR (28)		37F	A02:A11	NR SU IP LU			IV	sequence	
Patient G		G	Patient		122.6	NLA	NR		440M	A02:A03	CE CL SU		3	IV		
Patient H		H	Patient		24.3	G	NR		480M	A02:A30	SU			IV		
Patient I		I	Patient		93.7	NLA	PR (12)		570M	A02:A03	SK SU			IV		
Patient J		J	Patient		109.0	M	PR (14)		550M	A02:A0205	DN SK SU			IV		
Patient K		K	Patient		130.0	M	NR		380M	A02:A11	BN SU CY LI PA			IV		
Patient L		L	Patient		137.0	M	NR-M		37F	A02:A11	BN IL SU GB LI LU			IV		
Patient M		M	Patient		77.0	NI	NR		40F	A02	SU			IV	vp clones CR	